The global non-injectable insulin market is estimated to be worth USD 1.7 billion in 2024. From 2024 to 2034, the market is projected to grow at a solid clip, registering a CAGR of 13.5%.
| Attributes | Key Insights |
|---|---|
| Global Non-injectable Insulin Market Size (2024E) | USD 1.7 billion |
| Market Value (2034F) | USD 6.1 billion |
| Value-based CAGR (2024 to 2034) | 13.5% |
Growing prevalence of diabetes worldwide is surging the demand for non-injectable insulin as patients seek more comfort and convenience from the treatment. Cultural considerations and healthcare providers' willingness to try new treatments are set to impact patient preferences and adoption of non-injectable insulin.
In the pharmaceutical industry, the non-injectable insulin market provides easy and less challenging alternatives to traditional insulin injections, such as transdermal patches, oral insulin, and inhalable insulin. The market is growing due to innovative developments in drug delivery technology, which have resulted in more dependable and effective non-injectable insulin replacements.
Technological innovations in non-injectable insulin delivery devices are estimated to improve consumer experience and adherence, resulting in revenue growth and placing firms as competitive leaders. By 2034, the market is anticipated to reach USD 6.1 billion.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
From 2019 to 2023, the market has prolonged due to patient preferences for non-injectable products, fueled by advantages such as convenience, simplicity of administration, and less discomfort. The market grew at a CAGR of 17.0% between 2019 and 2023.
The advent of inhalable insulin was one of the prevalent changes in the non-injectable insulin industry. Exubera, the first inhalable insulin medication, received the United States Food & Drug Administration (FDA) approval in 2006. Afrezza's release, despite initial disappointment due to poor demand and concerns about its bulky inhaler, renewed interest in inhalable insulin, enhancing consumer acceptability.
The FDA's regulatory control, in particular, has had a key impact on the market. For non-injectable insulin solutions, strict regulatory criteria for safety, effectiveness, and quality standards have impacted clinical trial designs, product development, and market access. Although Afrezza is still the only FDA-approved inhaled insulin medication in the United States, several manufacturers have looked into creating comparable goods.
The demand for insulin is competitive. It is projected to spur innovation, enhance product offerings, and increase diabetes patients' treatment alternatives. By 2034, the market is set to surge at a CAGR of 13.5%, which is comparatively low from 2019 to 2023.
Insulin that is not injectable is now delivered more effectively because of developments in inhalation technology, including creating more accurate and effective inhaler devices. Sustained drug delivery methods, formulation optimization, and device design innovations are projected to boost market growth and enhance patient outcomes for non-injectable insulin treatment.
Leading companies are researching oral insulin formulations that can withstand digestive system conditions. They are potentially revolutionizing diabetes management by offering a comfortable, painless alternative to needles. Diabetes patients seek non-injectable insulin replacements due to needle phobia and daily hassles, pushing pharmaceutical companies to invest in unique products.
Regulatory bodies such as the FDA are evaluating and approving new insulin products, leading to a booming market. Pharmaceutical companies are collaborating with healthcare providers, IT companies, and research organizations to propel the development of insulin-delivery products.
Leading healthcare companies and professionals prioritize cost and accessibility to ensure all patients can access enhanced non-injectable solutions, fueling the market. The design process for insulin delivery systems is vital for diabetes patients, considering their preferences and input, thereby accelerating demand for non-injectable insulin.
The table below shows the estimated growth rates of the leading five nations. South Korea, Japan, and the United Kingdom are set to emerge as profitable markets for companies, recording CAGRs of 16.0%, 15.2%, and 14.6%, respectively, through 2034.
| Countries | Projected CAGR (2024 to 2034) |
|---|---|
| United States | 13.8% |
| United Kingdom | 14.6% |
| China | 14.2% |
| South Korea | 16.0% |
| Japan | 15.2% |
The table below highlights key countries’ market revenues. The United States and China are forecast to remain the leading consumers of non-injectable insulin, with predicted valuations of USD 1.1 billion and USD 1.0 billion, respectively, in 2034.
| Countries | Market Value (2034) |
|---|---|
| United States | USD 1.1 billion |
| United Kingdom | USD 243.2 million |
| China | USD 1.0 billion |
| South Korea | USD 395.6 million |
| Japan | USD 665.7 million |
Japan's non-injectable insulin market is projected to reach a valuation of around USD 665.7 million by 2034. Japan, with its high diabetes prevalence, urbanization, and growing healthcare infrastructure, is experiencing increased demand for innovative diabetes management solutions.
The growing awareness of insulin's convenience and reduced pain are projected to fuel the adoption of non-injectable insulin in Japan. Government initiatives and collaborations with pharmaceutical companies further promote market growth, positioning Japan as a leading player in the market.
The competitive landscape in Japan's pharmaceutical industry is projected to spur innovation and sales expansion in the non-injectable insulin market. Leading companies in Japan invest in research & development to enhance product formulas, delivery methods, and patient care services to set themselves apart.
Demand for non-injectable insulin is increasing in the United States, with a projected CAGR of 13.8% through 2034. MannKind Corporation's Afrezza is the primary insulin product for adults with diabetes, developed in the United States. It is a rapid-acting inhaled insulin available in powder form and regulated through an inhaler device.
Patient adoption and acceptability of non-injectable insulin treatments is determined by a number of factors, including cost, affordability, availability, efficacy, and safety. Campaigns for patient & healthcare professional education and awareness are planned to promote the benefits and increase adoption of non-injectable insulin therapy in the United States.
The non-injectable insulin market is projected to increase in South Korea at a CAGR of 16.0% through 2034. South Korea is anticipated to undergo research & development activities to improve pharmaceutical compositions, delivery systems, and patient outcomes, fueling demand for non-injectable insulin. Collaborations among pharmaceutical firms, healthcare providers, and regulatory bodies are vital for pouring innovation and increasing access to non-injectable insulin therapy in South Korea.
Pills stand atop the pile in the product type segment. The segment is anticipated to grow at a CAGR of 13.3% by 2034. Drug stores remain the predominant mode of distribution channel.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Pills (Product) | 13.3% |
| Drug Stores (Distribution Channel) | 13.1% |
Oral insulin tablets are projected to rise at 13.3% CAGR through 2034. The marketing and distribution of insulin pills is dependent on permission from health authorities such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA). Oral medicines are projected to improve insulin therapy adherence in individuals who find injections uncomfortable or unpleasant.
In January 2023, for instance, researchers at the UiT Norway's Arctic University published a paper in Nature Nanotechnology. It states that out of the 425 million people suffering from diabetes across the globe, nearly 75 million inject themselves with insulin. However, this can soon change as researchers have found a novel method to supply smart insulin. It can be taken by the patient as a capsule or with any other food item, including chocolates.
Drug stores provide non-injectable medicines and specialized healthcare services, whereas specialty pharmacies focus on complicated medical conditions such as diabetes. Drug stores offer prescription counseling, adherence monitoring, and insurance help, making them important to ensure easy and convenient pharmaceutical access.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
A few leading companies and manufacturers dominate the market. They are launching new products worldwide to meet consumer demands and investing in research & development. Key companies also use several growth strategies to inflate their market reach and customer base, including mergers, acquisitions, partnerships, and collaborations.
For instance
The industry is set to reach a valuation of USD 1.7 billion in 2024.
Demand for non-injectable insulin is set to rise at 13.5% CAGR by 2034.
The industry is projected to reach USD 6.1 billion in 2034.
Novo Nordisk, Sanofi, and Eli Lilly are the key players.
The pills segment is estimated to hold a significant market share in 2024.
| Estimated Market Size (2024E) | USD 26,408.7 million |
|---|---|
| Projected Market Value (2034F) | USD 57,544.5 million |
| Value-based CAGR (2024 to 2034) | 8.1% |
| Market Size (2022E) | USD 21.11 billion |
|---|---|
| Market Size (2032F) | USD 120 billion |
| Value CAGR (2022 to 2032) | 19.0% |
| Market Value (2023) | USD 35 billion |
|---|---|
| Market Forecast Value (2033) | USD 66 billion |
| Market Expected CAGR (2023 to 2033) | 6.5% |
| Market Value (2022) | USD 5.5 billion |
|---|---|
| Market Value (2032) | USD 14.8 billion |
| Market CAGR (2022 to 2032) | 10.3% |
Explore Therapy Area Insights
View Reports
Non-injectable Insulin Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
